Skip to content

Borrelia burgdorferi IgG Antibody (Serum/Plasma) - Fluorescent Antibody Test

Published: August 9, 2026Updated: August 15, 2026

This test detects antibodies to *Borrelia burgdorferi*, the bacterium responsible for Lyme disease, using a fluorescent antibody technique on serum or plasma.

Quick summary

["This test helps diagnose Lyme disease by identifying your immune system’s response to the infection."]

Medically reviewed by WellAlly Editorial TeamLast reviewed August 15, 2026Editorial policy

Key facts at a glance

LOINC
48888-2
Short code
COX1G
Synonyms
C burnet Ph1 IgG Titr Fld IF
Category
chemistry
Sample
serum
Container
Sterile, leak-proof collection tube (serum separator tube or plain red-top tube)
Units
N/A
Ref low
0
Ref high
1
Critical range
— – 799 N/A
Fasting
false
Population
adult
Sex
all
Age range
≥ 0 years
Method
Immunofluorescence Assay (IFA) for detection of IgG antibodies to Coxiella burnetii phase 1 antigen
CPT
86638
SNOMED
122445009
Specimen volume
1-2 mL of serum (minimum 0.5 mL)
Stability
Stable for 7 days at 2-8°C; for longer storage, freeze at -20°C or below. Avoid repeated freeze-thaw cycles.
Hemolysis max
100
Lipemia max
100
Icterus max
50
TAT
24–72 hours
Order
routine

What This Test Measures

The test looks for specific antibodies (IgG) produced by your immune system in response to *Borrelia burgdorferi*. These antibodies develop after infection and can remain detectable for months or years. The fluorescent antibody technique highlights these antibodies if they are present, allowing lab technicians to identify them under a microscope.

Why It’s Done

Your healthcare provider may order this test if you have symptoms like fever, fatigue, joint pain, or a characteristic rash (e.g., bull’s-eye rash) that could suggest Lyme disease. It’s also used to confirm a diagnosis in people with suspected early or late-stage infection.

A blood sample is drawn from a vein in your arm, and the serum or plasma is separated for testing. This sample is then processed and analyzed in a lab using the fluorescent antibody method.

No special preparation is needed, but avoid taking antibiotics for at least two weeks before testing, as they may affect antibody levels.

A positive result indicates the presence of *Borrelia burgdorferi* antibodies, suggesting past or current infection. However, false positives can occur, so results are often interpreted alongside clinical symptoms and other tests. A negative result means no detectable antibodies were found, but this doesn’t rule out Lyme disease entirely.

A positive result may prompt further testing (e.g., Western blot) to confirm the diagnosis. If you’re at risk of Lyme disease (e.g., due to outdoor activities in endemic areas), follow-up testing may be recommended even with negative results.

Reference range

Negative: <1:16; Equivocal: 1:16; Positive: ≥1:32. Phase 1 IgG titers ≥1:200 are considered diagnostic of chronic Q fever.N/A

Specimen: serum

No special patient preparation required. Fasting is not necessary. Patients should inform their healthcare provider about any recent antibiotic use, as antibiotic therapy may affect antibody titers.

Clinical interpretation

How abnormal results are interpreted and what conditions they suggest.

Lyme disease is a tick-borne illness that can cause a range of symptoms, including joint pain, neurological issues, and heart problems if untreated. Early detection and treatment with antibiotics can prevent complications. Antibody testing helps confirm infection but isn’t always definitive in early stages, so symptoms and medical history remain critical for diagnosis.

Short name

Borrelia IgG FTA

Frequently asked questions

How soon after infection can I expect this test to show positive?
Antibodies typically develop within 2–6 weeks after infection, but some people may take longer. Early-stage Lyme disease may initially test negative, so symptoms and clinical evaluation are key. If you suspect exposure, discuss testing timelines with your provider.
Can I get a false positive on this test?
Yes, false positives can occur due to cross-reactions with other bacteria or autoimmune conditions. Your provider may order additional tests (e.g., Western blot) to verify results and rule out other causes of symptoms.
This test primarily detects IgG antibodies, which appear later in infection. Early-stage Lyme disease (e.g., erythema migrans rash) may not show detectable antibodies initially. Early treatment is often based on symptoms and clinical judgment rather than lab results alone.
If results are unclear, your healthcare provider may repeat testing, order additional tests (e.g., ELISA or Western blot), or consider other diagnostic approaches. They’ll use your symptoms, medical history, and risk factors to guide next steps.
  1. 1
  2. 2
  3. 3

Click any link to access the full source. PubMed Central (PMC) links provide free full-text access.

This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.

Medical Disclaimer

This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.

If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.

Medically reviewed by WellAlly Editorial Team Last reviewed August 15, 2026. · Read our editorial policy